GBD-220

N/A

Report date: 2026/04/03 14:48:17

Base Information

Drug NameGBD-220

Drug Alias NameGBD-220GBD220

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionAnti-CD3Anti-CD19Anti-BCMA

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesGenor Biopharma Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesGenor Biopharma Co Ltd

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A